Industrials

The rollout includes 2,000+ transit time improvements along with enhanced guaranteed delivery and tracking and logistics capabilities

MONTREAL and MCLEAN, Va., June 25, 2026 (GLOBE NEWSWIRE) -- NorthStar Earth & Space Inc. (“NorthStar” or the “Company”), a global leader in Space Situational Awareness (“SSA”) and Space Domain Awareness (“SDA”), and Viking Acquisition Corp. I (“Viking”) (NYSE: VACI), a special purpose acquisition company, announced today the public filing of their joint registration statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) in connection with their proposed business combination (the “Business Combination Agreement”) announced on April 17, 2026, available here.

Stewart Bain, Founder and Chief Executive Officer of NorthStar, said, “The public filing of our registration statement represents an important milestone in the process of becoming a public company. The market demand for NorthStar’s differentiated space-based intelligence platform requires accelerating our long-term growth strategy. Increased access to capital and global awareness, inherent with a public company, will enable us to expand capabilities and deepen customer support by delivering more critical insights to stakeholders through our services.”

Communiqué de presse

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others.